In a $2.4 billion deal, Deciphera Pharmaceuticals Inc. is merging with Ono Pharmaceutical Co. Ltd. Ono is acquiring all of Deciphera’s outstanding stock shares for $25.60 each in cash. The merger helps Osaka, Japan-based Ono strengthen its oncology portfolio and its presence in the U.S.
Boston-based South Korean biotech Genosco Inc. said on April 25 that it passed a technology review required for the special listing track on the tech-heavy Kosdaq market, as it readies an IPO on the Korea Exchange.
Antibody-drug conjugates are the hot spot for deals in Asia, but investors questioned whether oncology is really the place to be, during the Asia Bio Partnering Forum in Singapore April 24 to 25.
Phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors potentially useful for the treatment of cancer have been described in a recent Scorpion Therapeutics Inc. patent.
Researchers from Shenyang Pharmaceutical University and affiliated organizations have reported the identification of a selective cyclin-dependent kinase 9 (CDK9) inhibitor, CLZX-205, being developed for the treatment of colorectal cancer.
Accession Therapeutics Ltd. has raised £25 million (US$31.3 million) to fund it through the generation of the first clinical data for its lead product, TROCEPT-01 (ATTR-01), and completion of IND-enabling studies for a second program. The internal early-stage pipeline will also be progressed.
Alligator Bioscience AB reported that Orion Corp. has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement.
Acrivon Therapeutics Inc.’s $130 million financing disclosed April 9 hiked confidence in then-pending data with ACR-368 (prexasertib), the selective small-molecule inhibitor that targets checkpoint kinase 1 (CHK1) and CHK2. Undergoing tests in a potentially registrational phase II trial across multiple tumor types, ACR-368 also raised the stakes for Boundless Bio Inc., which is developing CHK1 inhibitor BBI-355.